Xeris Biopharma Holdings, Inc. (XERS)

Last Closing Price: 6.72 (2025-12-04)

Company Description

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $203.07M
Net Income (Most Recent Fiscal Year) $-54.84M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 4.20
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -5.88%
Net Margin (Trailing 12 Months) -5.88%
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -4.66%
Current Ratio (Most Recent Fiscal Quarter) 1.93
Quick Ratio (Most Recent Fiscal Quarter) 1.35
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) 0.70
Book Value per Share (Most Recent Fiscal Quarter) $-0.20
Earnings per Share (Most Recent Fiscal Quarter) $0.00
Earnings per Share (Most Recent Fiscal Year) $-0.33
Diluted Earnings per Share (Trailing 12 Months) $-0.10
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 165.92M
Free Float 155.19M
Market Capitalization $1.12B
Average Volume (Last 20 Days) 2.77M
Beta (Past 60 Months) 0.57
Percentage Held By Insiders (Latest Annual Proxy Report) 6.47%
Percentage Held By Institutions (Latest 13F Reports) 42.75%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%